冰岛deCODE genetics
　DECODE基因解码公司成立于1996年，目前员工约480人，总部设在雷克雅未克，是世界上首家利用人类基因图谱研究相关疾病药物的企业，在疾病遗传基因研究领域处于世界领先地位。公司收集并建立人类基因和医疗数据库，从中研究并找出基因和一般常见病害的关联，开发基因检测软件，研制阻断性治疗药物，近年来，公司利用冰岛及世界各地相对同质的人类资源分析确定了心脏病、糖尿病等50多种常见病的遗传基因图谱，相关基因检测软件和药物也在研发中。

Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. deCODE employs its capabilities to develop DNA-based tests and personal genome scans to better understand individual risk and empower prevention. It also licenses its tests and intellectual property to partners, and provides leading- edge contract services to companies and research institutions around the globe.

Through its CLIA- and CAP-certified laboratory deCODE offers a growing range of risk assessment tests. These include deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProstateCancer™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme™, the company enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits.

deCODE’s therapeutic portfolio includes DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051, a compound targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer’s disease and other conditions. The company intends to partner or directly outlicense these programs for further clinical development.